Skip to main content

Advertisement

Table 8 The impact of expression status of metabolism-related proteins on prognosis by univariate analysis

From: Metabolic phenotypes in primary unknown metastatic carcinoma

Clinicopathologic parameters No. of patients (n = 59*) (%) Overall survival
No. of cases Patient death   Median survival (95% CI) (months) P -value
Glut-1 (T)      0.101
 Negative 34 13   74 (49–98)  
 Positive 25 5   55 (42–68)  
Glut-1 (S)    N/A   N/A
 Negative 59 18   84 (66–102)  
 Positive 0 0   N/A  
CAIX (T)      0.272
 Negative 51 17   82 (63–101)  
 Positive 8 1   54 (30–79)  
CAIX (S)      N/A
 Negative 57 18   N/A  
 Positive 2 0   N/A  
MCT4 (T)      0.759
 Negative 19 5   87 (59–115)  
 Positive 40 13   80 (57–103)  
MCT4 (S)      0.631
 Negative 34 9   94 (73–115)  
 Positive 25 9   43 (29–57)  
GLS1 (T)      0.139
 Negative 39 10   49 (38–60)  
 Positive 20 8   73 (42–103)  
GLS1 (S)      0.721
 Negative 50 15   84 (65–104)  
 Positive 9 3   46 (22–69)  
GDH (T)      1.000
 Negative 7 2   28 (14–39)  
 Positive 52 16   85 (66–104)  
GDH (S)      0.786
 Negative 44 13   90 (72–109)  
 Positive 15 5   40 (19–60)  
ASCT2 (T)      0.506
 Negative 38 13   78 (54–101)  
 Positive 21 5   36 (27–45)  
ASCT2 (S)      0.227
 Negative 56 16   87 (68–105)  
 Positive 3 2   16 (1–32)  
ATP synthase (T)      0.653
 Negative 2 1   10 (10–10)  
 Positive 57 17   85 (67–104)  
ATP synthase (S)      0.535
 Negative 48 14   88 (68–107)  
 Positive 11 4   23 (12–34)  
SDHA (T)      0.906
 Negative 3 1   28 (13–43)  
 Positive 56 17   84 (66–103)  
SDHA (S)      0.588
 Negative 44 13   90 (70–109)  
 Positive 15 5   37 (15–58)  
SDHB (T)      0.166
 Negative 23 5   86 (56–115)  
 Positive 36 13   79 (57–102)  
SDHB (S)      0.923
 Negative 51 16   84 (65–103)  
 Positive 8 2   27 (16–37)  
  1. *Out of 77 patients, clinical follow-up data were available in 59 patients.